Reprogramming through the overexpression of the Yamanaka factors captures some of the changes seen in early embryonic development, creating youthful embryonic stem cells from old germline cells. This process not only erases cell state, transforming adult somatic cells into induced pluripotent stem cells, but also shifts epigenetic patterns towards a more youthful configuration. This reversal of age-related mitochondrial dysfunction and other harmful changes in cell behavior is the focus of current research efforts. The goal now is to achieve partial reprogramming to rejuvenate cells in aged living tissue, striking a balance between epigenetic rejuvenation and avoiding pluripotency and cancer risks. As efforts in partial reprogramming gain momentum, they are poised to rival senolytic therapies in the race to combat aging. With increased funding and rapid progress, the field of partial reprogramming holds great promise for rejuvenation. Research in this area is advancing quickly, offering hope for new therapies that could slow aging in humans. The recent discovery of reprogramming-induced rejuvenation (RIR), which allows old cells to revert to a younger state through partial reprogramming, has opened up new possibilities for anti-aging interventions. Studies have shown that RIR can enhance physiological function, rejuvenate cells on multiple levels, and reverse the epigenetic clock, among other benefits. Despite concerns about safety and the need for further research, the potential of partial reprogramming for rejuvenation therapies is significant. Understanding the nature of rejuvenation and its translational potential, as well as assessing the risks and benefits, will be crucial for advancing this promising approach.